Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alrex vs Patanol in Seasonal Allergic Conjunctivitis
NCT01435460Phase 3Completed
- Sponsor
- Bausch + Lomb
- Start
- Aug 2010
- Primary completion
- Apr 2011
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of loteprednol etabonate in seasonal allergic conjunctivitis (SAC) (2 arms), sponsored by Bausch + Lomb. Primary endpoints: Bulbar Conjunctival Injection at Day 15 and Ocular Itching at Day 15. Started Aug 2010; status: completed.
02
Drugs
loteprednol etabonate
03
Conditions
seasonal allergic conjunctivitis (SAC)
Beyond the preview
Go deeper on NCT01435460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01435460.